Net earnings fell to $4.37 billion, or $1.60 per share, in the latest quarter, from $4.42 billion, or $1.61 per share, a year earlier. Last month, J&J reported aggressive Remicade discounting contributed to its average drug price decline of 4.6% in 2017. Questex LLC. Caruso said in a conference call with analysts and investors. Before Tuesday, the stock had fallen 5.7% for the year, while the S&P 500 has gained 0.2%.
J&J's best-selling drug Remicade (infliximab) saw its sales drop about 17% year over year in the first quarter — and an even steeper 22% decline in the U.S. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after purchasing an additional 3,023,110 shares during the last quarter. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.51.